Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/Î”M2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age